Anteris Technologies Global (ASX:AVR) Total Current Assets : A$117.87 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Anteris Technologies Global Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Anteris Technologies Global's total current assets for the quarter that ended in Dec. 2024 was A$117.87 Mil.

Anteris Technologies Global Total Current Assets Historical Data

The historical data trend for Anteris Technologies Global's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Global Total Current Assets Chart

Anteris Technologies Global Annual Data

Trend

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

8.26

26.19

18.21

36.53

117.87

Anteris Technologies Global Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial															18.21	24.99	36.53	17.04	117.87

Anteris Technologies Global Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Anteris Technologies Global's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	111.253	+	3.55	+	0.81	+	2.261
	=	117.87

Anteris Technologies Global's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	111.253	+	3.55	+	0.81	+	2.261
	=	117.87

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Anteris Technologies Global (ASX:AVR) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Anteris Technologies Global's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	111.253	-	28.449	+	0.75 * 0.328	+	0.5 * 0.81
=	83.46

Anteris Technologies Global Total Current Assets Related Terms

Thank you for viewing the detailed overview of Anteris Technologies Global's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies Global Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Global Corp (ASX:AVR) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

AVR:USA

Address

9 Sherwood Road, Level 3, Suite 302, Toowong, QLD, AUS, 4066

Website

https://www.anteristech.com

Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.